A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs

In this study that used a PBPK modeling approach, it was shown that CYP3A4 enzyme activity in the liver was not affected by trofinetide coadministration, but trofinetide was predicted to be a weak inhibitor of intestinal CYP3A4 metabolism after oral administration at therapeutic doses.PMID:38307724 | DOI:10.1016/j.clinthera.2023.12.007

Source: Clinical Therapeutics - February 2, 2024 Category: Drugs & Pharmacology Authors: Mona Darwish James M Youakim Inger Darling Viera Lukacova Joel S Owen Heather Bradley Source Type: research